The price of PAVmed Inc (NASDAQ:PAVM) shares last traded on Wall Street rose 3.77% to $0.21.
PAVM stock price is now -23.56% away from the 50-day moving average and -43.15% away from the 200-day moving average. The market capitalization of the company currently stands at $25.94M.
With the price target of $8, Cantor Fitzgerald recently initiated with Overweight rating for PAVmed Inc (NASDAQ: PAVM).
In other news, Glennon Michael J, Director bought 100,000 shares of the company’s stock on Dec 07. The stock was bought for $62,320 at an average price of $0.62. Upon completion of the transaction, the Director now directly owns 250,000 shares in the company, valued at $52500.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 06, Director Glennon Michael J bought 88,000 shares of the business’s stock. A total of $56,082 was incurred on buying the stock at an average price of $0.64. This leaves the insider owning 150,000 shares of the company worth $31500.0. A total of 10.31% of the company’s stock is owned by insiders.
A candlestick chart of PAVmed Inc (NASDAQ: PAVM) showed a price of $0.2100 on Wednesday morning. During the past 12 months, PAVmed Inc has had a low of $0.20 and a high of $0.83. The fifty day moving average price for PAVM is $0.2810 and a two-hundred day moving average price translates $0.3779 for the stock.
The latest earnings results from PAVmed Inc (NASDAQ: PAVM) was released for Sep, 2023. The net profit margin was -4679.67% and return on equity was -754.31% for PAVM. The company reported revenue of $0.79 million for the quarter, compared to $76000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 940.79 percent.
PAVmed Inc(PAVM) Company Profile
PAVmed Inc. operates as a medical device company in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett’s Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
